赵洪云 - 中山大学 - 肿瘤防治中心

个人简介

学习及工作经历： 1993年—1998年：昆明医学院就读 1998年—2000年：昆明医学院第一附属医院院工作 2000年—2003年：中山医科大学就读硕士生 2003年—至今：中山大学肿瘤医院工作；期间（2007年—2011年）攻读在职博士生

研究领域

擅长肺癌、鼻咽癌的化疗、靶向治疗及新药临床试验。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Zhou T, Zheng L, Hu Z, Zhang Y, Fang W, Zhao Y, Ge J, Zhao H, Zhang L. The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment. Scientific reports. 2015;5:7683.(IF: 5.078) 2.Zhao HY, Chen GY, Huang Y, Li XL, Feng JF, Shi MQ, Cheng Y, Ma LX, Zhang YP, Gu CP, Song XQ, Zhou D, Zhang L. Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807): An Open-Label, Single Arm, Multicenter Phase II Study. Medicine. Jan 2015;94(2):e249. (IF: 4.867) 3.Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao LP, Guo Y, Huang Y, Tian Y, Xie D, Zhang L. Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients. OncoTargets and therapy. 2014;7:1301-1310. (IF: 1.342) 　4.Zhao H, Fan Y, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Wang M, Zhang L. Final overall survival results from a phase III, randomised, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Dec 24 2014. (IF: 5.800) 5.Zhao H, Zhao Y, Guo Y, Huang Y, Lin S, Xue C, Xu F, Zhang Y, Zhao L, Hu Z, Zhang L. Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. OncoTargets and therapy. 2013;6:811-818. (IF: 1.342) 6.Zhao H, Huang Y, Xue C, Chen Y, Hou X, Guo Y, Zhao L, Hu Z, Huang Y, Luo Y, Zhang L. Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. PloS one. 2013;8(1):e54674. (IF: 3.534) 7.Zhao HY, Huang H, Hu ZH, Huang Y, Lin SX, Tian Y, Lin TY. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. Anti-cancer drugs. Jun 2012;23(5):534-542. (IF: 1.891) 8.He LR, Zhao HY, Li BK, Liu YH, Liu MZ, Guan XY, Bian XW, Zeng YX, Xie D. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. International journal of cancer. Journal international du cancer. Jul 1 2011;129(1):143-150. (IF: 5.007) 9.Zhang J, Huang Y, Li X, Guo Y, Zhao Y, Xue C, Hu Z, Zhang L, Zhao H. The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution. OncoTargets and therapy. 2012;5:349-355. (IF: 1.342) 10.He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, Guan XY, Bian XW, Zeng YX, Xie D. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Annals of oncology. Aug 2010;21(8):1675-1681. (IF: 6.578) 11.Zhao HY, Zhang Y, Huang H, Chen LK, Xu GC, Zhang L. [Efficacy of erlotinib on advanced non-small cell lung cancer]. Chinese journal of cancer. Apr 2008;27(4):393-399.